Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Gupta is currently an Oncology Fellow at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

For information on Dr. Gupta see the following links - 

Hopkins Medicine Kimmel Cancer Center

ASCO

Not On My Watch
dbrock
Dr. Arjun Gupta shares with us this story of his first oncology patient.
Author
Arjun Gupta, MD, Advisory Board Member, GRACE Faculty
Image
We are excited to be able to share the following article provided by a member of the GRACE Fellows Ambassador Program, Dr. Arjun Gupta.

The article, originally written for JAMA Oncology, is an amazing and warm piece about Dr. Gupta's experience with his first patient as a first-year oncology fellow.  To view the full article on the JAMA website, please follow this link, or scroll down to see the full text.  

 

We are very much looking forward to collaborating with Dr. Gupta on supportive care programs over the next year. 
Thank you, Dr. Gupta, for allowing us to share this work! 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on